The guidance provides sponsors and review staff with the Agency’s thinking about the analysis, interpretation, and management of issues related to the use of multiple endpoints in clinical trials.
The guidance provides sponsors and review staff with the Agency’s thinking about the analysis, interpretation, and management of issues related to the use of multiple endpoints in clinical trials.
No comments yet. Be the first to share your thoughts.